{"id":"https://openalex.org/W2000818290","doi":"https://doi.org/10.3109/07357900902918460","title":"Single Agent Vinflunine in the Salvage Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Trial of the Sarah Cannon Research Consortium","display_name":"Single Agent Vinflunine in the Salvage Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Trial of the Sarah Cannon Research Consortium","publication_year":2009,"publication_date":"2009-10-26","ids":{"openalex":"https://openalex.org/W2000818290","doi":"https://doi.org/10.3109/07357900902918460","mag":"2000818290","pmid":"https://pubmed.ncbi.nlm.nih.gov/20158340"},"language":"en","primary_location":{"id":"doi:10.3109/07357900902918460","doi":"https://doi.org/10.3109/07357900902918460","is_oa":false,"landing_page_url":"https://doi.org/10.3109/07357900902918460","pdf_url":null,"source":{"id":"https://openalex.org/S121125331","display_name":"Cancer Investigation","issn_l":"0735-7907","issn":["0735-7907","1532-4192"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Investigation","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2000818290"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065917441","display_name":"John Daniel Hainsworth","orcid":"https://orcid.org/0000-0002-2848-6546","observed_orcids":["https://orcid.org/0000-0002-2848-6546"]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]},{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"John D. Hainsworth","raw_affiliation_strings":["Sarah Cannon Research Institute Nashville, Tennessee 37203, USA. John.hainsworth@scresearch.net","Sarah Cannon Research Institute, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute Nashville, Tennessee 37203, USA. John.hainsworth@scresearch.net","institution_ids":["https://openalex.org/I4210100810"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, London, United Kingdom","institution_ids":["https://openalex.org/I172427033"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036076577","display_name":"Anthony A. Meluch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]},{"id":"https://openalex.org/I4210153992","display_name":"Oncology Hematology Care","ror":"https://ror.org/04gqr8882","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210153992"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Anthony A. Meluch","raw_affiliation_strings":["Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA","Sarah Cannon Research Institute, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA","institution_ids":["https://openalex.org/I4210135086","https://openalex.org/I4210153992"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, London, United Kingdom","institution_ids":["https://openalex.org/I172427033"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050610940","display_name":"Cassie Michelle Lane","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]},{"id":"https://openalex.org/I4210153992","display_name":"Oncology Hematology Care","ror":"https://ror.org/04gqr8882","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210153992"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Cassie M. Lane","raw_affiliation_strings":["Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA","Sarah Cannon Research Institute, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA","institution_ids":["https://openalex.org/I4210135086","https://openalex.org/I4210153992"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, London, United Kingdom","institution_ids":["https://openalex.org/I172427033"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018054038","display_name":"David Robert Spigel","orcid":"https://orcid.org/0000-0003-3215-9465","observed_orcids":["https://orcid.org/0000-0003-3215-9465"]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]},{"id":"https://openalex.org/I4210153992","display_name":"Oncology Hematology Care","ror":"https://ror.org/04gqr8882","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210153992"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"David R. Spigel","raw_affiliation_strings":["Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA","Sarah Cannon Research Institute, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA","institution_ids":["https://openalex.org/I4210135086","https://openalex.org/I4210153992"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, London, United Kingdom","institution_ids":["https://openalex.org/I172427033"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072308451","display_name":"Howard A. Burris","orcid":"https://orcid.org/0000-0002-1501-2931","observed_orcids":["https://orcid.org/0000-0002-1501-2931"]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]},{"id":"https://openalex.org/I4210153992","display_name":"Oncology Hematology Care","ror":"https://ror.org/04gqr8882","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210153992"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Howard A. Burris","raw_affiliation_strings":["Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA","Sarah Cannon Research Institute, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA","institution_ids":["https://openalex.org/I4210135086","https://openalex.org/I4210153992"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, London, United Kingdom","institution_ids":["https://openalex.org/I172427033"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112254132","display_name":"Jitendra G. Gandhi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]},{"id":"https://openalex.org/I4210153992","display_name":"Oncology Hematology Care","ror":"https://ror.org/04gqr8882","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210153992"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Jitendra G. Gandhi","raw_affiliation_strings":["Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA","Sarah Cannon Research Institute, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA","institution_ids":["https://openalex.org/I4210135086","https://openalex.org/I4210153992"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, London, United Kingdom","institution_ids":["https://openalex.org/I172427033"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Edward J. Crane","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]},{"id":"https://openalex.org/I4210153992","display_name":"Oncology Hematology Care","ror":"https://ror.org/04gqr8882","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210153992"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Edward J. Crane","raw_affiliation_strings":["Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA","Sarah Cannon Research Institute, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA","institution_ids":["https://openalex.org/I4210135086","https://openalex.org/I4210153992"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, London, United Kingdom","institution_ids":["https://openalex.org/I172427033"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004137427","display_name":"Michael A. Stipanov","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]},{"id":"https://openalex.org/I4210153992","display_name":"Oncology Hematology Care","ror":"https://ror.org/04gqr8882","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210153992"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Michael A. Stipanov","raw_affiliation_strings":["Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA","Sarah Cannon Research Institute, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA","institution_ids":["https://openalex.org/I4210135086","https://openalex.org/I4210153992"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, London, United Kingdom","institution_ids":["https://openalex.org/I172427033"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5073724595","display_name":"F. Anthony Greco","orcid":"https://orcid.org/0009-0009-4578-0630","observed_orcids":["https://orcid.org/0009-0009-4578-0630"]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]},{"id":"https://openalex.org/I4210153992","display_name":"Oncology Hematology Care","ror":"https://ror.org/04gqr8882","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210153992"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"F. Anthony Greco","raw_affiliation_strings":["Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA","Sarah Cannon Research Institute, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA","institution_ids":["https://openalex.org/I4210135086","https://openalex.org/I4210153992"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, London, United Kingdom","institution_ids":["https://openalex.org/I172427033"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.212,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":{"value":0.55552611,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"28","issue":"3","first_page":"275","last_page":"279"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vinflunine","display_name":"vinflunine","score":1.0},{"id":"https://openalex.org/keywords/castration-resistant-prostate-cancer","display_name":"castration-resistant prostate cancer","score":0.9710000157356262},{"id":"https://openalex.org/keywords/salvage-therapy","display_name":"salvage therapy","score":0.902999997138977},{"id":"https://openalex.org/keywords/vinca-alkaloids","display_name":"vinca alkaloids","score":0.8450000286102295},{"id":"https://openalex.org/keywords/metastatic-prostate-cancer","display_name":"metastatic prostate cancer","score":0.9200000166893005},{"id":"https://openalex.org/keywords/docetaxel-resistance","display_name":"docetaxel resistance","score":0.8989999890327454},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9700000286102295},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.949999988079071},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.5479999780654907}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8351532220840454},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.8249502778053284},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.7933030128479004},{"id":"https://openalex.org/C2777096885","wikidata":"https://www.wikidata.org/wiki/Q220925","display_name":"Vinca","level":2,"score":0.7018056511878967},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6394662857055664},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6068803071975708},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.501610517501831},{"id":"https://openalex.org/C2780775027","wikidata":"https://www.wikidata.org/wiki/Q17141389","display_name":"Salvage therapy","level":3,"score":0.5006124973297119},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.49439120292663574},{"id":"https://openalex.org/C2776553716","wikidata":"https://www.wikidata.org/wiki/Q3559405","display_name":"Vinca alkaloid","level":5,"score":0.4540281593799591},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4535847008228302},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.439027339220047},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4192935824394226},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.40981924533843994},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.29268234968185425},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.09583553671836853},{"id":"https://openalex.org/C2779429289","wikidata":"https://www.wikidata.org/wiki/Q408977","display_name":"Vincristine","level":4,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000972","descriptor_name":"Antineoplastic Agents, Phytogenic","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009919","descriptor_name":"Orchiectomy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D011471","descriptor_name":"Prostatic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011471","descriptor_name":"Prostatic Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D014747","descriptor_name":"Vinblastine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014747","descriptor_name":"Vinblastine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D014747","descriptor_name":"Vinblastine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016879","descriptor_name":"Salvage Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017430","descriptor_name":"Prostate-Specific Antigen","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.3109/07357900902918460","doi":"https://doi.org/10.3109/07357900902918460","is_oa":false,"landing_page_url":"https://doi.org/10.3109/07357900902918460","pdf_url":null,"source":{"id":"https://openalex.org/S121125331","display_name":"Cancer Investigation","issn_l":"0735-7907","issn":["0735-7907","1532-4192"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Investigation","raw_type":"journal-article"},{"id":"pmid:20158340","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20158340","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer investigation","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":14,"referenced_works":["https://openalex.org/W1868905893","https://openalex.org/W1979300931","https://openalex.org/W1979967697","https://openalex.org/W2064885466","https://openalex.org/W2066984265","https://openalex.org/W2080439368","https://openalex.org/W2112766786","https://openalex.org/W2120292596","https://openalex.org/W2139248078","https://openalex.org/W2155679349","https://openalex.org/W2249078508","https://openalex.org/W2474019072","https://openalex.org/W3009994097","https://openalex.org/W3041047318"],"related_works":["https://openalex.org/W2252541857","https://openalex.org/W3190079414","https://openalex.org/W4300968061","https://openalex.org/W2184945417","https://openalex.org/W2284177532","https://openalex.org/W2261266915","https://openalex.org/W2996148399","https://openalex.org/W2586700330","https://openalex.org/W930942117","https://openalex.org/W1970499757"],"abstract_inverted_index":{"Patients":[0],"with":[1,12,23,48],"metastatic":[2,67],"prostate":[3,68],"cancer":[4],"resistant":[5],"to":[6],"hormones":[7],"and":[8,70],"docetaxel":[9],"were":[10],"treated":[11],"vinflunine":[13],"(320":[14],"mg/m(2)":[15],"every":[16],"21":[17],"days),":[18],"a":[19,57],"new":[20],"vinca":[21],"alkaloid":[22],"improved":[24],"preclinical":[25],"activity.":[26],"Only":[27],"1":[28],"of":[29,60,65],"36":[30],"patients":[31],"(3%)":[32],"had":[33],"partial":[34],"response;":[35],"the":[36,51,63],"median":[37],"progression-free":[38],"survival":[39],"(PFS)":[40],"was":[41,45],"2.1":[42],"months.":[43],"Treatment":[44],"well":[46],"tolerated,":[47],"myelosuppression":[49],"as":[50],"only":[52],"frequent":[53],"toxicity.":[54],"Vinflunine":[55],"has":[56],"low":[58],"level":[59],"activity":[61],"in":[62],"treatment":[64],"refractory":[66],"cancer,":[69],"should":[71],"not":[72],"be":[73],"further":[74],"developed":[75],"for":[76],"this":[77],"indication.":[78]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}